Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
J Mol Neurosci
2018 Nov 01;663:383-389. doi: 10.1007/s12031-018-1184-1.
Show Gene links
Show Anatomy links
OIP5 Expression Sensitize Glioblastoma Cells to Lomustine Treatment.
Rodrigues-Junior DM
,
Biassi TP
,
Carlin V
,
Buri MV
,
Torrecilhas AC
,
Bortoluci KR
,
Vettore AL
.
???displayArticle.abstract???
Glioblastoma (GBM) is an incurable disease ranked among the deadliest solid cancers worldwide. A better understanding on the molecular aspects of this malignancy could contribute to the development of new treatment strategies and help to improve survival rates. Previously, our group had shown that GBM patients expressing the cancer/testis antigen Opa Interacting Protein 5 (OIP5) present a longer survival period than the OIP5-negative group. The main goal of this study was to evaluate the OIP5 contribution to GBM tumorigenesis and assess the role of OIP5 in GBM cell response to lomustine, an alkylating agent used in the treatment of this malignancy. So, the effect of OIP5 knockdown was evaluated in A172 and T98G GBM cell lines. Our results demonstrated that downregulation of the OIP5 stimulates glioma cell viability and inhibits cell death-induced necrosis prompted by lomustine. In conclusion, our data shows that OIP5 expression in GBM cells seems to be able to enhance lomustine cytotoxic effects, reinforcing that this gene is a potential therapeutic target and putative molecular biomarker for treatment response in GBM.
2012/14837-7 Fundação de Amparo à Pesquisa do Estado de São Paulo (BR), 2010/20218-2 Fundação de Amparo à Pesquisa do Estado de São Paulo (BR), 2011/15118-1 Fundação de Amparo à Pesquisa do Estado de São Paulo, 2012/01597-8 Fundação de Amparo à Pesquisa do Estado de São Paulo, 300936/2015-0 Conselho Nacional de Desenvolvimento Científico e Tecnológico
Adamson,
Glioblastoma multiforme: a review of where we have been and where we are going.
2009, Pubmed
Adamson,
Glioblastoma multiforme: a review of where we have been and where we are going.
2009,
Pubmed
Batchelor,
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.
2013,
Pubmed
Berte,
Targeting Homologous Recombination by Pharmacological Inhibitors Enhances the Killing Response of Glioblastoma Cells Treated with Alkylating Drugs.
2016,
Pubmed
Chun,
OIP5 is a highly expressed potential therapeutic target for colorectal and gastric cancers.
2010,
Pubmed
Freitas,
Expression of cancer/testis antigens is correlated with improved survival in glioblastoma.
2013,
Pubmed
Gilbert,
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.
2013,
Pubmed
Gong,
Expression of Opa interacting protein 5 (OIP5) is associated with tumor stage and prognosis of clear cell renal cell carcinoma.
2013,
Pubmed
Harvey,
Enhanced anticancer properties of lomustine in conjunction with docosahexaenoic acid in glioblastoma cell lines.
2015,
Pubmed
Koinuma,
Characterization of an Opa interacting protein 5 involved in lung and esophageal carcinogenesis.
2012,
Pubmed
Lee,
Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide.
1994,
Pubmed
Livak,
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.
2001,
Pubmed
Mobasheri,
Cancer/Testis OIP5 and TAF7L Genes are Up-Regulated in Breast Cancer.
2015,
Pubmed
Nakamura,
Opa interacting protein 5 (OIP5) is a novel cancer-testis specific gene in gastric cancer.
2007,
Pubmed
Pegg,
Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase.
1995,
Pubmed
Staberg,
Inhibition of histone deacetylases sensitizes glioblastoma cells to lomustine.
2017,
Pubmed
Stupp,
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
2005,
Pubmed
Stupp,
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
2009,
Pubmed
Taal,
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
2014,
Pubmed
Weller,
EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma.
2014,
Pubmed
Wick,
Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma.
2010,
Pubmed
Williams,
Using the yeast two-hybrid system to identify human epithelial cell proteins that bind gonococcal Opa proteins: intracellular gonococci bind pyruvate kinase via their Opa proteins and require host pyruvate for growth.
1998,
Pubmed
Yang,
Anandamide induces cell death through lipid rafts in hepatic stellate cells.
2010,
Pubmed
Yazarloo,
Expression analysis of four testis-specific genes AURKC, OIP5, PIWIL2 and TAF7L in acute myeloid leukemia: a gender-dependent expression pattern.
2013,
Pubmed
Zimmermann,
Annexin V/7-AAD staining in keratinocytes.
2011,
Pubmed
